Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway

References

• Yaffe MJ, Jong RA. Adjunctive ultrasonography in breast cancer screening. Lancet. 2016;387(10016):313–314. doi:10.1016/S0140-6736(15)00787-4
   PubMed Web of Science ®Google Scholar
• Braunstein LZ, Taghian AG, Niemierko A, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 2017;161(1):173–179. doi:10.1007/s10549-016-4031-5
   PubMed Web of Science ®Google Scholar
• Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786–3788. doi:10.1172/JCI60534
   PubMed Web of Science ®Google Scholar
• Guiu S, Michiels S, André F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Ann Oncol. 2012;23(12):2997–3006. doi:10.1093/annonc/mds586
   PubMed Web of Science ®Google Scholar
• Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121(1):8–16. doi:10.1002/cncr.28914
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–150. doi:10.1002/path.4280
   PubMed Web of Science ®Google Scholar
• Giuli MV, Giuliani E, Screpanti I, Bellavia D, Checquolo S. Notch signaling activation as a hallmark for triple-negative breast cancer subtype. J Oncol. 2019;2019:8707053. doi:10.1155/2019/8707053
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36(12):822–846. doi:10.1016/j.tips.2015.08.009
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
   PubMedGoogle Scholar
• Han Q, Sun M-L, Liu W-S, et al. Upregulated expression of ACTL8 contributes to invasion and metastasis and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1749–1763. doi:10.2147/OTT.S185858
   PubMed Web of Science ®Google Scholar
• Li B, Zhu J, Meng L. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma. Mol Med Rep. 2019;19(2):877–884. doi:10.3892/mmr.2018.9716
   PubMed Web of Science ®Google Scholar
• Ma S, Wang X, Zhang Z, Liu D. Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells. Thorac Cancer. 2020;11(3):526–536. doi:10.1111/1759-7714.13247
   PubMed Web of Science ®Google Scholar
• Yao J, Caballero OL, Yung WK, et al. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res. 2014;2(4):371–379. doi:10.1158/2326-6066.CIR-13-0088
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–619. doi:10.1038/nrg1879
   PubMed Web of Science ®Google Scholar
• Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45–55. doi:10.1016/j.ctrv.2018.11.001
   PubMed Web of Science ®Google Scholar
• Gasparri ML, Besharat ZM, Farooqi AA, et al. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. J Cancer Res Clin Oncol. 2018;144(12):2313–2318. doi:10.1007/s00432-018-2737-y
   PubMed Web of Science ®Google Scholar
• Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397–406. doi:10.1007/s10549-018-4697-y
   PubMed Web of Science ®Google Scholar
• Lei S, Fan P, Wang M, et al. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2020;20(2):1630–1636. doi:10.3892/etm.2020.8809
   PubMed Web of Science ®Google Scholar
• Yue X, Li M, Chen D, Xu Z, Sun S. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. Exp Ther Med. 2018;16(5):3921–3928. doi:10.3892/etm.2018.6675
   PubMed Web of Science ®Google Scholar
• Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 2014;508(7494):103–107. doi:10.1038/nature13119
   PubMed Web of Science ®Google Scholar
• Balafoutas D, Zur Hausen A, Mayer S, et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer. 2013;13(1):271. doi:10.1186/1471-2407-13-271
   PubMedGoogle Scholar
• Dhodapkar MV, Osman K, Teruya-Feldstein J, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003;3:9.
   PubMedGoogle Scholar
• Li L, Cheng GH, Chen C, Ma DM, Deng XC. Actin‑like protein 8 executes a promoting function in the malignant progression of endometrial cancer: identification of a promising biomarker. Biosci Biotechnol Biochem. 2020;84(6):1160–1167. doi:10.1080/09168451.2020.1736508
   PubMed Web of Science ®Google Scholar
• Sharma VR, Gupta GK, Sharma AK, Batra N, Sharma DK, Joshi A. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr Pharm Des. 2017;23(11):1633–1638. doi:10.2174/1381612823666161116125218
   PubMed Web of Science ®Google Scholar
• Reddy D, Ghosh P, Kumavath R. Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin signaling pathways in human cancers. Front Oncol. 2019;9:1469. doi:10.3389/fonc.2019.01469
   PubMed Web of Science ®Google Scholar
• Li ZQ, Qu M, Wan HX, Wang H, Deng Q, Zhang Y. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(22):9978–9987. doi:10.26355/eurrev_201911_19564
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562. doi:10.1038/nrc2664
   PubMed Web of Science ®Google Scholar